Relationship Between ATG Genetic Variants and Blood Pressure or Hypertension: A MetaAnalysis of Epidemiologic Studies

Data Abstract Form

1. Study:
__________________________________________________________________________________________________________________________
Authors name: __________________________
Publication Year: _________________________
Country: ________________________________
2. Study
Follow-up
Design
Corhort study
__1
duration:
Case-control study
__2
Cross-sectional study
__3
3. Participants Characteristics
Control (group
(group 3)
All
Case (group 1) 2)
1). Age:
Average: ____yrs
____yrs
____yrs
____yrs
Range: ____ to ____yrs
2). Sex:
3). Race:
European descent:
African descent:
Asian descent:
Hispanic descent
White:
Black:
Other
(Specify):___________ :
4). Taking antihypertension medication:
5). History of CVD:
6). BMI (mean, SD):

M: ____%

F: ___%

____ to ____yrs

____ to ____yrs

____ to ____yrs

M: ____%
___%

M: ____%
___%

M: ____% F: ___
%

F:

F:

____%
___%
___%

___%
___%
___%

___%
___%
___%

___%
___%
___%

___%
___%

___%
___%

___%
___%

___%
___%

___%

___%

___%

___%
_______%

_______%
_______%
_______

_______%
_______%
_______

_______%
_______%
_______

_______%
_______

4.
Outcome

Systolic Blood Pressure

Diastolic Blood Pressure
Hypertension
Definition of hypertension:
BP Measurement device:
Number of BP measures:

5.
Exposure RS #
1). _________
2). _________
3). _________
4). _________
5). _________
6). _________
6.
1). No. of Participants

Nucleotide
substitution
________________
________________
________________
________________
________________
________________

Variant
1:_______
___ ____
Genotype ____
___ ____
No. ____

__1
__2
__3
1). SBP>139,
DBP>89
1).
sphygmomanometer

2). Clinical record

2). Other:
___________________________

Amino Acid
Substitution
___________________
___________________
___________________
___________________
___________________
___________________

HW p-value
________________
________________
________________
________________
________________
________________

Variant 2:__________
___ ____
____

Variant
3:________
___ ____

____

___

___

____

____

____

____

Alleles

MAF

Call rate
_______________
_______________
_______________
_______________
_______________
_______________

______________
______________
______________
______________
______________
______________

____
____
____
____
____
____

Variant
4:_______
___ ____
____
___ ____
____

Variant
5:_______
___ ____
____
___ ____
____

Variant
4:_______
___ ____
____
___ ____
____

Variant
5:_______
___ ____
____
___ ____
____

2). No. of cases

Variant
1:_______
___ ____
Genotype ____
___ ____
No. ____

Variant 2:__________
___ ____
____

Variant
3:________
___ ____

____

___

___

____

____

____

____

7. Confounders controlled (including matching and adjustment):

8. Method of accounting for population substructure (confounding by ethnicity):

1). Restriction; 2). Adjust for self-reported race;

Genomic control;

3). Ancestry informative Markers;

4). Principle component analysis; 5).

6). Other: ______________________________________

9. Relative risk/Odds ratio (S.E.) for hypertension:

Pop.

Model
variant 1: ___________
Genotype

All

Euro.

Co-dom.
(RR, OR,
HR, 95%
CI, P)
Dom.
(RR, OR,
HR, 95%
CI, P)
Rec.
(RR, OR,
HR, 95%
CI, P)
Add.
(OR, 95%
CI;
, Se)
Co-dom.
(RR, OR,
HR, 95%

variant 2:
_________
Genotype

variant 3:
_________
Genotype

variant 4:
_________
Genotype

variant 5:
_________
Genotype

Asian

Africa

CI, P)
Dom.
(RR, OR,
HR, 95%
CI, P)
Rec.
(RR, OR,
HR, 95%
CI, P)
Add.
(OR, 95%
CI;
, Se)
Co-dom.
(RR, OR,
HR, 95%
CI, P)
Dom.
(RR, OR,
HR, 95%
CI, P)
Rec.
(RR, OR,
HR, 95%
CI, P)
Add.
(OR, 95%
CI;
, Se)
Co-dom.
(RR, OR,
HR, 95%
CI, P)
Dom.
(RR, OR,
HR, 95%
CI, P)
Rec.
(RR, OR,
HR, 95%
CI, P)

Hisp.

Other
____

Men

Add.
(OR, 95%
CI;
, Se)
Co-dom.
(RR, OR,
HR, 95%
CI, P)
Dom.
(RR, OR,
HR, 95%
CI, P)
Rec.
(RR, OR,
HR, 95%
CI, P)
Add.
(OR, 95%
CI;
, Se)
Co-dom.
(RR, OR,
HR, 95%
CI, P)
Dom.
(RR, OR,
HR, 95%
CI, P)
Rec.
(RR, OR,
HR, 95%
CI, P)
Add.
(OR, 95%
CI;
, Se)
Co-dom.
(RR, OR,
HR, 95%
CI, P)
Dom.

Wome
n

(RR, OR,
HR, 95%
CI, P)
Rec.
(RR, OR,
HR, 95%
CI, P)
Add.
(OR, 95%
CI;
, Se)
Co-dom.
(RR, OR,
HR, 95%
CI, P)
Dom.
(RR, OR,
HR, 95%
CI, P)
Rec.
(RR, OR,
HR, 95%
CI, P)
Add.
(OR, 95%
CI;
, Se)